Subject: Diabodies Target Tumors with Mutated RAS, p53 - Cancer Currents Blog
From: National Cancer Institute <[email-masked]>
To: [email-masked]
Date: Fri, 02 Apr 2021 14:32:36 +0000

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

Researchers Create Modified Antibodies to Target RAS and p53 in Cancer

04/02/2021

Researchers have developed synthetic antibodies, called diabodies, that block the activity of two of the most notorious cancer-related proteins, RAS and p53. In experiments in mice, the synthetic antibodies shrank tumors with these mutated proteins.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237)

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Help

This email was sent to [email-masked] using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892